19 augusti, 2024 08:00 iCoat Medicals medgrundare och Head of Chemistry Prof. Yuji Teramura belönas med prestigefyllt pris från Japanese Society for Biomaterials Läs mer
25 juni, 2024 08:00 iCoat Medical får positiv feedback från EMA kring sin planerade kliniska studie EMPIRe och det avslutade prekliniska programmet Läs mer
13 juni, 2024 11:45 iCoat Medical genomförde framgångsrikt långtidsuppföljningsdelen av sin kliniska studie ATMIRe Läs mer
10 juni, 2024 13:00 iCoat Medicals prekliniska resultat presenterade vid den prestigefyllda World Biomaterials Congress i Sydkorea Läs mer
19 mars, 2024 16:00 iCoat Medicals CMO Dr. Alireza Biglarnia vinner anslag för transplantationsforskning Läs mer
21 februari, 2024 16:28 iCoat Medical forms a Scientific Advisory Board to strengthen its transplant expertise Läs mer
19 februari, 2024 16:00 iCoat Medical’s upcoming Phase 2b study EMPIRe with iCM012 fundamental to updated clinical development plan Läs mer
20 november, 2023 16:00 Swedish MPA looks favorably on iCoat Medical’s continued and expanded development of iCM012 Läs mer
19 september, 2023 08:00 iCoat Medical meddelar positiva resultat från fas 1/2a-studien ATMIRe vid njurtransplantation Läs mer
10 maj, 2023 17:35 iCoat Medical completes enrollment in First In Human study of TUM012 in kidney transplantation Läs mer
20 april, 2023 16:30 COMMUNIQUÉ FROM ICOAT MEDICAL AB’S (PUBL) ANNUAL GENERAL MEETING 20 APRIL 2023 Läs mer
17 december, 2022 10:28 COMMUNIQUÉ FROM ICOAT MEDICAL AB’S (PUBL) EXTRAORDINARY GENERAL MEETING 16 DECEMBER 2022 Läs mer
19 oktober, 2022 17:00 The U.S. Food and Drug Administration has granted iCoat Medical Orphan Drug Designation for TUM012 in the United States Läs mer
11 oktober, 2022 13:00 ICOAT MEDICAL ANNOUNCES SECOND INTERIMDATA FROM ONGOING FIRST-IN-HUMAN TRIAL WITH NOVEL DRUG TUM012 Läs mer
10 augusti, 2022 ICOAT MEDICAL ANNOUNCES INTERIM DATA FROM ONGOING FIRST-IN-HUMAN TRIAL WITH NOVEL DRUG TUM012 Läs mer
13 juni, 2022 iCoat Medical to present at the 14th International Conference on Complement Therapeutics in Rhodes, Greece in June 2022 Läs mer
4 juni, 2022 iCoat Medical to present at the 29th International Congress of The Transplantation Society in Buenos Aires, Argentina in September 2022 Läs mer
25 april, 2022 iCoat Medical’s Chief Medical Officer Alireza Biglarnia featured in article from Njurfonden Läs mer
21 april, 2022 The European Commission has granted iCoat Medical Orphan Drug Designation for TUM012 in the EU Läs mer
22 december, 2021 iCoat Medical receives approval from the Swedish MPA and starts its First in Human trial at Skåne University Hospital Läs mer
21 december, 2021 Communiqué from iCoat Medical’s (PUBL) extraordinary general meeting 15 December 2021 Läs mer
28 november, 2021 The European Union Intellectual Property Office grants iCoat Medical funding for IP assessment Läs mer
15 november, 2021 Carl Bjartmar is proposed as a new member to iCoat Medical’s Board of Directors Läs mer
24 juli, 2021 iCoat Medical has successfully raised 40 MSEK in a Pre-IPO to fund its upcoming First In Human-trial Läs mer